New therapy targeting RSK3 to improve heart failure outcomes
Official title: RSK3 Anchoring Disruptor Therapy for Heart Failure
Funded at Cardiac Rsk3 Inhibitors, LLC · NIH-10929421 · Data updated 2026-11-12
This study is testing a new treatment that uses a virus to deliver a special peptide to heart cells, which could help prevent heart failure by stopping harmful changes in the heart, and it aims to improve heart function and quality of life for people with heart issues.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cardiac Rsk3 Inhibitors, LLC NIH-funded |
| Lab location | 1 site (Los Altos, United States) |
| Project start | September 14, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,982,787 |
| NIH project number | 5R44HL167349-02 |
| Project ID | NIH-10929421 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with heart failure or those at high risk of developing heart failure due to conditions like hypertension or previous heart attacks.
✕Less likely to help
Patients with heart failure caused by non-cardiac factors or those who do not respond to conventional heart failure treatments may not benefit from this research.
What this research studies
This research investigates a novel therapy aimed at disrupting the interaction between RSK3 and a specific scaffold protein in cardiac cells, which is crucial for preventing heart failure. By using adeno-associated viruses to deliver a peptide that blocks this interaction, the study aims to inhibit pathological remodeling of the heart that occurs during conditions like pressure overload and myocardial infarction. The approach has shown promise in mouse models, suggesting it could lead to improved heart function and quality of life for patients with heart failure.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves survival and quality of life for patients with heart failure.
How similar studies have gone: Other research has shown success with similar therapeutic approaches targeting intracellular signaling pathways in heart disease, indicating potential for this novel strategy.
Where this research is happening
-
Cardiac Rsk3 Inhibitors, LLC
Los Altos, United States Active
Researchers
- Principal investigator: Cividini, Federico — Cardiac Rsk3 Inhibitors, LLC
- Study coordinator: Cividini, Federico
Related research
Other NIH-funded projects on the same topics.
-
AI-supported heart failure diagnosis and management in Rwanda
Aiming to help people with suspected heart failure in Rwanda get faster, more accurate diagnoses and better care using AI-guided ultrasound and care protocols.
-
AI-assisted heart failure diagnosis in Rwanda using focused ultrasound
An NIH-funded project will test whether AI-enhanced, easy-to-use heart ultrasound can help non-experts diagnose and manage heart failure in Rwanda.
-
HF endotypes in heart failure using ethical multi-modal AI and molecular data
A patient-friendly project that uses advanced AI and multiple kinds of health data to identify distinct heart failure subtypes that could guide personalized care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Digital-first heart failure care delivery in Uganda
A targeted program in Uganda tests a digital care plan to help people with heart failure manage their symptoms at home.
-
Digital-first heart failure care delivery in Uganda
A study to test digital self-care tools to help people with heart failure in Uganda manage symptoms and stay healthier.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.